Date: 2014-03-06
Type of information:
phase: 2a
Announcement:
Company: Hepatera (Russia)
Product: Myrcludex B
Action mechanism:
Disease: hepatitis B
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On March 6, 2014, Maxwell Biotech Venture Fund has announced that its portfolio company Hepatera has completed enrollment of Phase IIa clinical trial of Myrcludex B, for hepatitis B. A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. The objectives of the ongoing Phase IIa clinical trial are to study safety and tolerability, as well as efficacy of several dose levels of Myrcludex B in comparison to standard therapy (nucleoside analogues). One specific aim is to study efficacy parameters not influenced by the standard therapy in the majority of cases.Preliminary results are expected in June 2014 and will be presented at international specialized conferences.
